This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huber, R. M. Articles by Ulm, K. Search for Related Content PubMed PubMed Citation Articles by Huber, R. M. Articles by Ulm, K.

Simultaneous Chemoradiotherapy Compared With Radiotherapy Alone After Induction Chemotherapy in Inoperable Stage IIIA or IIIB Non–Small-Cell Lung Cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy Group

Rudolf M. Huber, Michael Flentje, Michael Schmidt, Barbara Pöllinger, Helga Gosse, Jochen Willner, Kurt Ulm

From the Pneumologie, Medizinische Klinik Innenstadt, and Strahlentherapie, University of Munich; Institut für Medizinische Statistik und Epidemiologie, Technical University of Munich, Munich; Klinik und Poliklinik für Strahlentherapie, and Pneumologie, Medizinische Klinik, University of Wuerzburg, Wuerzburg; and the Robert-Koch-Klinik, Leipzig; Germany

Address reprint requests to Rudolf M. Huber, PhD, MD, Pneumologie, Medizinische Klinik Innenstadt, University of Munich, Ziemssenstrasse 1, 80336 Munich, Germany; e-mail: huber{at}med.uni-muenchen.de

PURPOSE: The aim of this study was to examine whether, after preceding induction chemotherapy, simultaneous chemoradiotherapy is superior to radiotherapy alone.

PATIENTS AND METHODS: Patients with non–small-cell lung cancer in inoperable stage IIIA or IIIB received induction chemotherapy with two cycles of paclitaxel 200 mg/m² and carboplatin area under the curve 6 every 3 weeks. Patients without progression at restaging after induction chemotherapy were randomly assigned to radiotherapy (60 Gy) or chemoradiotherapy (paclitaxel 60 mg/m² weekly). The primary end point was overall survival; secondary end points were time to progression, response, and toxicity.

RESULTS: Three hundred three patients entered the study, and 276 completed induction chemotherapy. Two hundred fourteen patients were randomly assigned (radiotherapy alone: n = 113; simultaneous chemoradiotherapy: n = 101). Median follow-up time of all randomly assigned patients was 13.6 months (interquartile range [IQR], 6.4 to 29.0 months), and median follow-up time of the subgroup of censored patients (n = 52) was 37.4 months (IQR, 5.9 to 57.0 months; maximum, 76.1 months). Toxicities during the induction phase were mild. During radiotherapy, overall toxicity rates were not significantly different between the two arms. Median survival times in the radiotherapy group and chemoradiotherapy group were 14.1 months (95% CI, 11.8 to 16.3 months) and 18.7 months (95% CI, 14.1 to 23.3 months; difference not statistically significant, P = .091). Median time to progression significantly favored simultaneous chemoradiotherapy (11.5 months; 95% CI, 8.3 to 14.7 months) versus radiotherapy alone (6.3 months; 95% CI, 5.0 to 7.6 months; P < .001, log-rank test).

CONCLUSION: Induction chemotherapy followed by chemoradiotherapy with weekly paclitaxel is feasible. Response, time to progression, and survival favor chemoradiotherapy compared with radiotherapy alone.

Supported by Bristol-Myers Squibb Co GmbH, Munich, Germany.

Presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31 to June 3, 2003; and at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				A. W. Blackstock and R. Govindan Definitive Chemoradiation for the Treatment of Locally Advanced Non Small-Cell Lung Cancer J. Clin. Oncol., September 10, 2007; 25(26): 4146 - 4152. [Abstract] [Full Text] [PDF]